prnewswire.comSEP 142 min read$ISRG

Intuitive announces expanded indication for da Vinci SP in Europe

Intuitive (ISRG) received CE mark approval for transvaginal gynecologic procedures using the da Vinci SP system in Europe, expanding its applications. The approval allows for less invasive options and potentially better recovery experiences. The system is already approved in the US, Japan, and Korea for various procedures.

Original reporting

prnewswire.com

Published Sep 14, 2026, 7:45 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 14, 2026, 8:27 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Intuitive announces expanded indication for da Vinci SP in Europe — source image — Source · prnewswire.com

Decision brief

The 30-second read

$ISRGBullishHigh

Why it matters

The CE mark expands the da Vinci SP's approved procedures, opening a new market segment in Europe.

Market read

First‑report regulatory approval that could boost ISRG's European revenue and reinforce its market leadership.

What to watch

Potential competition from other robotic platforms and the need for surgeon training could temper impact.

Relevance 7/10Novelty 8/10Timing: today

Background

Intuitive Surgical is a leading developer of robotic surgical systems, with the da Vinci platform used worldwide.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ISRGBullishHigh confidence

Context

Intuitive Surgical received CE mark approval for transvaginal gynecologic procedures for its da Vinci SP system in Europe.

Expected impact

Short-term upside as investors price in additional revenue opportunity.

Evidence & confidence

Regulatory approval for a new surgical indication is a material catalyst for a large‑cap medtech company.

Market effects

Sector

Strengthens the minimally invasive surgery segment and may boost related device makers.

Regional

European hospitals gain access to a new robotic surgery option, supporting regional medtech growth.

Global

Adds to Intuitive's global footprint, reinforcing its leadership in robotic surgery worldwide.

Counterpoint

What could challenge this read

The approval may not translate into immediate sales if adoption is slow or reimbursement is limited.

Key entities

Company
Intuitive Surgical
Manufacturer of the da Vinci robotic surgery systems.
Regulator
European regulatory authorities
Granted the CE mark for the new transvaginal gynecologic indication.

Read at source ← All news

SEP 15

$ISRGHighAI 8/10

Intuitive receives CE mark for transvaginal use of da Vinci SP system

Intuitive Surgical (ISRG) received CE mark approval for its da Vinci SP system for transvaginal gynecological procedures in Europe, expanding its use in women's health. The system, already approved for other surgeries, allows single-incision operations, potentially improving recovery and outcomes. It is also approved in the US, Japan, and Korea.

yahoo.com2 min

SEP 13

$GSMed

Robots Everywhere: Goldman Sachs Now Sees 6.5 Million Humanoid Robots by 2035

Goldman Sachs projects 6.5 million humanoid robots will be shipped globally by 2035, representing a $138 billion market opportunity. Companies like Tesla, TSMC, Teradyne, and NVIDIA are positioned to benefit, with some already showing significant revenue growth. A potential AI slowdown is cited as a risk to this forecast.

yahoo.com3 min

SEP 10

$IARTMedAI 8/10

Q2 Earnings Outperformers: Integra LifeSciences (NASDAQ:IART) And The Rest Of The Surgical Equipment & Consumables - Specialty Stocks

Integra LifeSciences (IART) reported flat Q2 revenue of $418.8M, meeting expectations. Teleflex (TFX) saw 28.9% revenue growth, beating estimates. LeMaitre (LMAT) missed expectations with 9.6% growth. Intuitive Surgical (ISRG) reported 18.5% growth, beating estimates. All stocks declined post-earnings, with IART down 17.7%, TFX flat, LMAT down 24.9%, and ISRG down 12.3%.

yahoo.com3 min

SEP 9

$ISRGMed

ISRG Stock Trading at its Cheapest in 10 Years: Should You Buy Now?

Intuitive Surgical (ISRG) trades at its lowest valuation in a decade, with a forward P/E of 30.26x, below its 10-year median. Despite a 40% decline, Q2 2026 revenue grew 19% to $2.89B, and EPS rose 28%. Management maintained 2026 da Vinci procedure growth forecast at 13.5-15.5%, citing international growth but noting U.S. and China uncertainties. ISRG's product pipeline includes da Vinci 5 and Ion systems, with innovations like SP procedures up 61%. Shares lag industry and sector, down 15% in 3

theglobeandmail.com3 min

SEP 8

$ISRGHighAI 9/10

Intuitive Wins Potential $420M DLA Surgical Robot Supply IDIQ - GovCon Wire

Intuitive Surgical (ISRG) won a potential $420M contract from the Defense Logistics Agency to supply surgical robots and related equipment over five years. The contract was awarded through a competitive process and will be funded through FY 2025. Work will be performed in California.

govconwire.com1 min

SEP 4

$ISRGMedAI 8/10

Intuitive Surgical Vs. Stryker: Wall Street Loves Both But One Has a Quiet Advantage That Will Make Investors Money

Intuitive Surgical (ISRG) and Stryker (SYK) both reported strong Q2 2026 earnings, with ISRG highlighting 85% recurring revenue and SYK showing 9.4% revenue growth. ISRG's da Vinci systems and SYK's MedSurg and Neurotechnology segments drove performance. ISRG's CEO noted portfolio strength, while SYK's CEO cited regained momentum. Analysts favor ISRG for its compounding moat and recurring revenue model, with 25 EPS revisions in 30 days.

aol.com2 min